Holen Sie sich die Stockscreener-App
41.62
1.30%
-0.62
Schlusskurs vom Vortag:
$42.24
Offen:
$42.06
24-Stunden-Volumen:
163.54K
Relative Volume:
0.19
Marktkapitalisierung:
$3.22B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-15.19
EPS:
-2.74
Netto-Cashflow:
$-156.53M
1W Leistung:
+4.27%
1M Leistung:
-6.40%
6M Leistung:
+33.66%
1J Leistung:
+4.27%
1-Tages-Spanne:
$41.20
$43.14
1-Wochen-Bereich:
$39.29
$43.14
52-Wochen-Spanne:
$26.74
$46.60
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Vergleichen Sie XENE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
41.63 | 3.26B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Published on: 2026-01-20 17:07:34 - baoquankhu1.vn
Campbell & CO Investment Adviser LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Companies Like Xenon Pharmaceuticals (NASDAQ:XENE) Are In A Position To Invest In Growth - Yahoo Finance
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ten new Xenon hires receive 42,300 stock options vesting over 4 years - Stock Titan
Trend Recap: Is Xenon Pharmaceuticals Inc stock undervalued right nowJuly 2025 Highlights & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Xenon Pharmaceuticals (XENE) Stock Analysis: Biotechnology Innovator with a 34% Upside Potential - DirectorsTalk Interviews
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon Pharmaceuticals CEO sells shares worth $2.21 million - MSN
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference - The Globe and Mail
New seizure and depression drug faces key 2026 test in late-stage trials - Stock Titan
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $62.00 at JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Increases Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $62.00 - MarketBeat
JPMorgan reiterates Overweight rating on Xenon Pharmaceuticals stock By Investing.com - Investing.com UK
XENE: JP Morgan Raises Xenon Pharmaceuticals' Price Target | XEN - GuruFocus
Can Xenon Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 Institutional & Daily Risk Controlled Trade Plans - Улправда
Is Xenon Pharmaceuticals Inc. stock supported by strong cash flowsMarket Sentiment Summary & Smart Allocation Stock Reports - Улправда
Can Xenon Pharmaceuticals Inc. stock maintain operating marginsQuarterly Trade Review & Stepwise Trade Execution Plans - Улправда
How rising interest rates impact Xenon Pharmaceuticals Inc. stockLong-Term Growth Stocks & We Spotted the Next Tesla – See Inside - Улправда
Why Xenon Pharmaceuticals Inc. stock remains undervaluedForecast Cut & Free Reliable Trade Execution Plans - ulpravda.ru
Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears - TechStock²
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month HighTime to Buy? - MarketBeat
Xenon to Showcase Neuroscience Pipeline at J.P. Morgan Healthcare Conference - TipRanks
Cantor Fitzgerald raises Xenon Pharmaceuticals stock price target to $55 By Investing.com - Investing.com UK
Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026 - Quiver Quantitative
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
(XENE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 40,000 Shares - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 3.8% – Should You Buy? - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Trading 3.8% HigherHere's Why - MarketBeat
Analysts Conflicted on These Healthcare Names: Lifecore Biomedical (LFCR) and Xenon (XENE) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
Commit To Purchase Xenon Pharmaceuticals At $32.50, Earn 25.8% Annualized Using Options - Nasdaq
Xenon announces new data on 48-month azetukalner OLE study data - MSN
Stifel reiterates Buy rating on Xenon Pharmaceuticals stock amid competitor setback - Investing.com Canada
Biohaven Misses The Mark In Depression Trial, Stock Falls - Sahm
Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Why (XENE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Pullback Watch: How rising interest rates impact Xenon Pharmaceuticals Inc. stockMarket Sentiment Report & Growth Focused Stock Pick Reports - Улправда
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Returns Recap: Why Xenon Pharmaceuticals Inc. stock remains undervaluedJuly 2025 PostEarnings & Capital Efficient Trading Techniques - Улправда
Will Xenon Pharmaceuticals Inc. stock outperform tech sector in 20252025 Price Targets & Long Hold Capital Preservation Plans - Улправда
Can Xenon Pharmaceuticals Inc. stock resist sector downturns2025 Price Momentum & Precise Entry and Exit Recommendations - Улправда
Xenon Pharmaceuticals Inc (XENE)’s stock price in review: A technical analysis - uspostnews.com
Is Xenon Pharmaceuticals Inc. stock attractive for passive investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 7th Largest Position - MarketBeat
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch PreparationSlideshow (NASDAQ:XENE) 2025-12-12 - Seeking Alpha
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):